Original article Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus

Objective: To compare glycemic goal achievement (HbA1c57%) in type 2 diabetes patients receiving initial metformin plus pioglitazone combination therapy and initial metformin monotherapy augmented with pioglitazone in a cohort follow-up study.

[1]  Alfonso T. Perez,et al.  Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM , 2009, Current medical research and opinion.

[2]  K. Kaku.  Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial , 2009, Current medical research and opinion.

[3]  V. Basevi.  Standards of medical care in diabetes--2007. , 2009, Diabetes care.

[4]  J. Rosenstock,et al.  Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy , 2008, Diabetes Care.

[5]  B. Hoogwerf,et al.  Managing Type 2 Diabetes: Going Beyond Glycemic Control , 2008, Journal of managed care pharmacy : JMCP.

[6]  G. Bolli,et al.  Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24‐week, randomized, double‐blind study * , 2007, Diabetes, obesity & metabolism.

[7]  D. Matthews,et al.  Pioglitazone and metformin. , 2007, Drugs of today.

[8]  G. Umpierrez,et al.  Metformin/rosiglitazone combination pill (Avandamet®) for the treatment of patients with Type 2 diabetes , 2007, Expert opinion on pharmacotherapy.

[9]  J. Rosenstock,et al.  Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes , 2007, Diabetes, obesity & metabolism.

[10]  B. Staels.  Metformin and pioglitazone: effectively treating insulin resistance , 2006, Current medical research and opinion.

[11]  M. Hanefeld,et al.  Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes , 2005, Diabetologia.

[12]  D. Johns,et al.  Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes , 2004, Current medical research and opinion.

[13]  L. Gaal,et al.  Rationale and options for combination therapy in the treatment of Type 2 diabetes , 2003, Diabetologia.

[14]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[15]  U. Smith,et al.  Pioglitazone: mechanism of action. , 2001, International journal of clinical practice. Supplement.

[16]  W. Manning,et al.  The Cost to Health Plans of Poor Glycemic Control , 1997, Diabetes Care.

[17]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[18]  J. Leahy.  Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes , 2008 .

[19]  S. Bagwe,et al.  A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. , 2007, Vascular health and risk management.